[May 03, 2012]

Research and Markets: India Pharmaceutical Industry Research and Forecast to 2016

Research and Markets (http://www.researchandmarkets.com/research/4lkwn7/india_pharmaceutic) has announced the addition of the "India Pharmaceutical Industry Research and Forecast to 2016" report to their offering.

The report titled India Pharmaceutical Industry Research and Forecast to 2016 offer detailed analysis on the country's bulk and formulations market which is sub-segmented into OTC, prescription drugs and generic drugs. It analyses major bio-pharmaceutical market segments, top therapeutic categories and traditional medicine market (herbal drugs, ayurvedic and homeopathy). Report also include SWOT analysis, major driving forces, industry growth barriers, Opportunities, Regulatory structure, Macro economy factors and Political environment of the country. Report also profile major players (domestic and international) and forecast industry and its segments' growth.

Generic drugs have a dominant position in the rapidly expanding Indian pharmaceutical industry. Inda is among one of the largest bulk drugs exporters but represent only one fourth of the total pharmaceutical market while formulation drugs account for the three fourth shares. Domestic market has showcased resilience during the economic crisis and has recorded a steady growth. Rising aging population indicates compelling opportunity for drug manufacturers to focus on bone health, dietary supplements and dementia and other age related diseases. Direct marketing is in its development stage in the country while multi level marketing companies are trying hard to understand spending behavior of middle class population in India.

Biopharmaceutical sector is expected to witness double digit growth led by major developments in therapeutic segment. Vaccines market (human and animal) is enjoying a continuous growth, dominated by human vaccine segment which accounted for more than three fourth of the market. In-licensing deals are expected to increase in domestic market to take the benefit of the lower R&D cost and manufacturing units of the domestic generic companies. The generic segment is expected to grow at a faster rate from 2012 onwards although industry may witness price erosion leading to reduced generic player's profit margin.

Key Topics Covered:

1. Indian Healthcare Industry

2. India Pharmaceutical Market Segments

3. Classification on the basis of API manufacturing segments

4. Growth Drivers

5. Opportunities

6. SWOT Analysis

7. Growth Barriers

8. Recent Pharmaceutical Industry M&A's

9. Regulatory Structure

10. Country Analysis

11. Industry Competition and Domestic Players Profiling

12. Appendix

Companies Mentioned

- Cipla

- Ranbaxy

- DR. Reddy's

- Sun Pharma

- Lupin

- Aurobindo pharmaceuticals

- GSK India

- Abbott India

- Pfizer

- Novartis India

For more information visit http://www.researchandmarkets.com/research/4lkwn7/india_pharmaceutic.

[ Back To Contact Center Solutions Homepage's Homepage ]